tiprankstipranks
Trending News
More News >

Elevation Oncology’s Chief Medical Officer Steps Down

Story Highlights
  • Elevation Oncology’s Chief Medical Officer, Dr. Jansen, stepped down on March 31, 2025.
  • Dr. Jansen’s severance includes a lump-sum payment, healthcare coverage, and accelerated equity vesting.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Elevation Oncology’s Chief Medical Officer Steps Down

An update from Elevation Oncology ( (ELEV) ) is now available.

On March 31, 2025, Elevation Oncology announced that Chief Medical Officer Dr. Valerie M. Jansen stepped down from her position. Dr. Jansen will receive severance benefits as per her agreement with the company, including a lump-sum payment, healthcare coverage, and accelerated vesting of equity awards. This transition is part of a separation agreement that includes standard legal provisions, potentially impacting the company’s operational dynamics and stakeholder relations.

More about Elevation Oncology

Elevation Oncology, Inc. operates in the biotechnology industry, focusing on the development of precision medicines for the treatment of cancer.

YTD Price Performance: -56.83%

Average Trading Volume: 2,627,012

Technical Sentiment Signal: Buy

Current Market Cap: $15.34M

See more data about ELEV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App